Skip to main content
Premium Trial:

Request an Annual Quote

Castle Biosciences Licenses BAP1 Gene from Wash U. for Melanoma Metastasis Detection

NEW YORK (GenomeWeb News) – Castle Biosciences today announced it has licensed the BAP1 gene from Washington University in St. Louis for detecting metastasis in patients with melanoma.

The Friendswood, Texas-based firm has begun validation studies for use of the technology in both uveal melanoma, or ocular melanoma, and cutaneous melanoma and plans to incorporate the gene into its DecisionDx-UM assay. It also has an option for use of the gene for other cancers.

Financial and other terms of the deal were not disclosed.

William Harbour and Anne Bowcock, both of Washington University, first reported on the link between BAP1 and metastasis in a 2010 Science article.

The DecisionDx-UM assay, developed at Washington University, is a gene expression assay for classifying primary uveal melanoma tumors as Class 1 or Class 2 tumors

Castle Bio also has an exclusive worldwide license from the university for the assay's underlying technology and has completed development and validation studies for it, the firm said. The assay is offered as a laboratory test service.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.